|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shuch B, Amin A, Armstrong AJ, Eble JN,
Ficarra V, Lopez-Beltran A, Martignoni G, Rini BI and Kutikov A:
Understanding pathologic variants of renal cell carcinoma:
Distilling therapeutic opportunities from biologic complexity. Eur
Urol. 67:85–97. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Braun DA, Hou Y, Bakouny Z, Ficial M,
Sant' Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA,
Elagina L, et al: Interplay of somatic alterations and immune
infiltration modulates response to PD-1 blockade in advanced clear
cell renal cell carcinoma. Nat Med. 26:909–918. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Choueiri TK and Motzer RJ: Systemic
therapy for metastatic renal-cell carcinoma. N Engl J Med.
376:354–366. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Choueiri TK, Fishman MN, Escudier B,
McDermott DF, Drake CG, Kluger H, Stadler WM, Perez-Gracia JL,
McNeel DG, Curti B, et al: Immunomodulatory activity of nivolumab
in metastatic renal cell carcinoma. Clin Cancer Res. 22:5461–5471.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Praefcke GJK and McMahon HT: The dynamin
superfamily: Universal membrane tubulation and fission molecules?
Nat Rev Mol Cell Biol. 5:133–147. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vestal DJ: The guanylate-binding proteins
(GBPs): Proinflammatory cytokine-induced members of the dynamin
superfamily with unique GTPase activity. J Interferon Cytokine Res.
25:435–443. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tretina K, Park ES, Maminska A and
MacMicking JD: Interferon-induced guanylate-binding proteins:
Guardians of host defense in health and disease. J Exp Med.
216:482–500. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu S, Yu X, Sun L, Zheng Y, Chen L, Xu H,
Jin J, Lan Q, Chen CC and Li M: GBP2 enhances glioblastoma invasion
through Stat3/fibronectin pathway. Oncogene. 39:5042–5055. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu B, Huang R, Fu T, He P, Du C, Zhou W,
Xu K and Ren T: GBP2 as a potential prognostic biomarker in
pancreatic adenocarcinoma. Peerj. 9:e114232021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu QY, Hoffman RM, Song J, Miao S, Zhang
J, Ding D and Wang D: Guanylate-binding protein 2 expression is
associated with poor survival and malignancy in clear-cell renal
cell carcinoma. Anticancer Res. 42:2341–2354. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Diaz-Montero CM, Rini BI and Finke JH: The
immunology of renal cell carcinoma. Nat Rev Nephrol. 16:721–735.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Junjun S, Yangyanqiu W, Jing Z, Jie P,
Jian C, Yuefen P and Shuwen H: Prognostic model based on six PD-1
expression and immune infiltration-associated genes predicts
survival in breast cancer. Breast Cancer. 29:666–676. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang H, Zhou Y, Zhang Y, Fang S, Zhang M,
Li H, Xu F, Liu L, Liu J, Zhao Q and Wang F: Subtyping of
microsatellite stability colorectal cancer reveals guanylate
binding protein 2 (GBP2) as a potential immunotherapeutic target. J
Immunother Cancer. 10:e0043022022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tang P, Qu W, Wu D, Chen S, Liu M, Chen W,
Ai Q, Tang H and Zhou H: Identifying and validating an
acidosis-related signature associated with prognosis and tumor
immune infiltration characteristics in pancreatic carcinoma. J
Immunol Res. 2021:38210552021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen H, Song Y, Deng C, Xu Y, Xu H, Zhu X,
Song G, Tang Q, Lu J and Wang J: Comprehensive analysis of immune
infiltration and gene expression for predicting survival in
patients with sarcomas. Aging (Albany NY). 13:2168–2183. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Haque M, Siegel RJ, Fox DA and Ahmed S:
Interferon-stimulated GTPases in autoimmune and inflammatory
diseases: Promising role for the guanylate-binding protein (GBP)
family. Rheumatology (Oxford). 60:494–506. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen S, Crabill GA, Pritchard TS, McMiller
TL, Wei P, Pardoll DM, Pan F and Topalian SL: Mechanisms regulating
PD-L1 expression on tumor and immune cells. J Immunother Cancer.
7:3052019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Iacovelli R, Nolè F, Verri E, Renne G,
Paglino C, Santoni M, Cossu Rocca M, Giglione P, Aurilio G, Cullurà
D, et al: Prognostic role of PD-L1 expression in renal cell
carcinoma. A systematic review and meta-analysis. Target Oncol.
11:143–148. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thompson RH, Dong H and Kwon ED:
Implications of B7-H1 expression in clear cell carcinoma of the
kidney for prognostication and therapy. Clin Cancer Res.
13:709s–715s. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cheng SW, Chen PC, Lin MH, Ger TR, Chiu HW
and Lin YF: GBP5 repression suppresses the metastatic potential and
PD-L1 expression in triple-negative breast cancer. Biomedicines.
9:3712021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ghandi M, Huang FW, Jané-Valbuena J,
Kryukov GV, Lo CC, McDonald ER III, Barretina J, Gelfand ET,
Bielski CM, Li H, et al: Next-generation characterization of the
cancer cell line encyclopedia. Nature. 569:503–508. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tang Z, Kang B, Li C, Chen T and Zhang Z:
GEPIA2: An enhanced web server for large-scale expression profiling
and interactive analysis. Nucleic Acids Res. 47((W1)): W556–W560.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gumz ML, Zou H, Kreinest PA, Childs AC,
Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, et
al: Secreted frizzled-related protein 1 loss contributes to tumor
phenotype of clear cell renal cell carcinoma. Clin Cancer Res.
13:4740–4749. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
von Roemeling CA, Radisky DC, Marlow LA,
Cooper SJ, Grebe SK, Anastasiadis PZ, Tun HW and Copland JA:
Neuronal pentraxin 2 supports clear cell renal cell carcinoma by
activating the AMPA-selective glutamate receptor-4. Cancer Res.
74:4796–4810. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lánczky A and Győrffy B: Web-based
survival analysis tool tailored for medical research (KMplot):
Development and implementation. J Med Internet Res. 23:e276332021.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vasaikar SV, Straub P, Wang J and Zhang B:
LinkedOmics: Analyzing multi-omics data within and across 32 cancer
types. Nucleic Acids Res. 46(D1): D956–D963. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou Y, Zhou B, Pache L, Chang M,
Khodabakhshi AH, Tanaseichuk O, Benner C and Chanda SK: Metascape
provides a biologist-oriented resource for the analysis of
systems-level datasets. Nat Commun. 10:15232019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Warde-Farley D, Donaldson SL, Comes O,
Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT,
et al: The GeneMANIA prediction server: Biological network
integration for gene prioritization and predicting gene function.
Nucleic Acids Res. 38((Web Server Issue)): W214–W220. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu
JS, Li B and Liu XS: TIMER: A web server for comprehensive analysis
of tumor-infiltrating immune cells. Cancer Res. 77:e108–e110. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q,
Li B and Liu XS: TIMER2.0 for analysis of tumor-infiltrating immune
cells. Nucleic Acids Res. 48((W1)): W509–W514. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brodaczewska KK, Szczylik C, Fiedorowicz
M, Porta C and Czarnecka AM: Choosing the right cell line for renal
cell cancer research. Mol Cancer. 15:832016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Furge KA, Chen J, Koeman J, Swiatek P,
Dykema K, Lucin K, Kahnoski R, Yang XJ and The BT: Detection of DNA
copy number changes and oncogenic signaling abnormalities from gene
expression data reveals MYC activation in high-grade papillary
renal cell carcinoma. Cancer Res. 67:3171–3176. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2 (−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cerezo M, Guemiri R, Druillennec S,
Girault I, Malka-Mahieu H, Shen S, Allard D, Martineau S, Welsch C,
Agoussi S, et al: Translational control of tumor immune escape via
the eIF4F-STAT1-PD-L1 axis in melanoma. Nat Med. 24:1877–1886.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cha JH, Chan LC, Li CW, Hsu JL and Hung
MC: Mechanisms controlling PD-L1 expression in cancer. Mol Cell.
76:359–370. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cerbone L, Cattrini C, Vallome G, Latocca
MM, Boccardo F and Zanardi E: Combination therapy in metastatic
renal cell carcinoma: Back to the future? Semin Oncol. 47:361–366.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Braun DA, Bakouny Z, Hirsch L, Flippot R,
Van Allen EM, Wu CJ and Choueiri TK: Beyond conventional
immune-checkpoint inhibition-novel immunotherapies for renal cell
carcinoma. Nat Rev Clin Oncol. 18:199–214. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wu T and Dai Y: Tumor microenvironment and
therapeutic response. Cancer Lett. 387:61–68. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gajewski TF, Schreiber H and Fu YX: Innate
and adaptive immune cells in the tumor microenvironment. Nat
Immunol. 14:1014–1022. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dai S, Zeng H, Liu Z, Jin K, Jiang W, Wang
Z, Lin Z, Xiong Y, Wang J, Chang Y, et al: Intratumoral
CXCL13+CD8+T cell infiltration determines
poor clinical outcomes and immunoevasive contexture in patients
with clear cell renal cell carcinoma. J Immunother Cancer.
9:e0018232021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Giraldo NA, Becht E, Pagès F, Skliris G,
Verkarre V, Vano Y, Mejean A, Saint-Aubert N, Lacroix L, Natario I,
et al: Orchestration and prognostic significance of immune
checkpoints in the microenvironment of primary and metastatic renal
cell cancer. Clin Cancer Res. 21:3031–3040. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Giraldo NA, Becht E, Vano Y, Petitprez F,
Lacroix L, Validire P, Sanchez-Salas R, Ingels A, Oudard S, Moatti
A, et al: Tumor-infiltrating and peripheral blood T-cell
immunophenotypes predict early relapse in localized clear cell
renal cell carcinoma. Clin Cancer Res. 23:4416–4428. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Braun DA, Street K, Burke KP, Cookmeyer
DL, Denize T, Pedersen CB, Gohil SH, Schindler N, Pomerance L,
Hirsch L, et al: Progressive immune dysfunction with advancing
disease stage in renal cell carcinoma. Cancer Cell. 39:632–648.e8.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Verhoeven Y, Tilborghs S, Jacobs J, De
Waele J, Quatannens D, Deben C, Prenen H, Pauwels P, Trinh XB,
Wouters A, et al: The potential and controversy of targeting STAT
family members in cancer. Semin Cancer Biol. 60:41–56. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhu H, Wang Z, Xu Q, Zhang Y, Zhai Y, Bai
J, Liu M, Hui Z and Xu N: Inhibition of STAT1 sensitizes renal cell
carcinoma cells to radiotherapy and chemotherapy. Cancer Biol Ther.
13:401–407. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kornepati AVR, Vadlamudi RK and Curiel TJ:
Publisher correction: Programmed death ligand 1 signals in cancer
cells. Nat Rev Cancer. 22:1902022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yi M, Niu M, Xu L, Luo S and Wu K:
Regulation of PD-L1 expression in the tumor microenvironment. J
Hematol Oncol. 14:102021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang H, Zhu C, He Z, Chen S, Li L and Sun
C: LncRNA PSMB8-AS1 contributes to pancreatic cancer progression
via modulating miR-382-3p/STAT1/PD-L1 axis. J Exp Clin Cancer Res.
39:1792020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Miao Q, Ge M and Huang L: Up-regulation of
GBP2 is associated with neuronal apoptosis in rat brain cortex
following traumatic brain injury. Neurochem Res. 42:1515–1523.
2017. View Article : Google Scholar : PubMed/NCBI
|
